Business Development Associate
AsimovSalary not specified
- Full Time
- Mid-level (3 to 4 years)
About Asimov
Asimov operates in the synthetic biology field, providing a combination of cells, genes, and software to assist in advanced genetic design. Their products include cloud-based software that allows clients in the biopharmaceutical industry to design, simulate, and optimize genetic systems. Additionally, they offer engineered GMP host cells that are used for therapeutic applications. Asimov distinguishes itself from competitors by guaranteeing high titer cell lines for monoclonal antibodies with a promise of '4 g/L or it's free,' which reduces risk for their clients. The company's goal is to enable biopharma companies to produce high-quality protein therapeutics and scalable viral vectors efficiently, supported by their in-house expertise in synthetic biology and process development.
Boston, MassachusettsHeadquarters
2017Year Founded
$199.1MTotal Funding
SERIES_BCompany Stage
AI & Machine Learning, BiotechnologyIndustries
51-200Employees
Risks
Competition from LatchBio's code-free biocomputing infrastructure challenges Asimov's software offerings.
Integration of The Foundry may lead to potential cultural clashes and operational disruptions.
Rapid data generation in synthetic biology may strain Asimov's data processing capabilities.
Differentiation
Asimov offers a '4 g/L or it's free' promise for monoclonal antibodies.
The LV Edge Producer System eliminates GMP plasmid costs and reduces process complexity.
Asimov integrates synthetic biology, computer-aided design, and machine learning for genetic design.
Upsides
Stable cell line development reduces costs and increases scalability in lentiviral production.
Acquisition of The Foundry enhances Asimov's expertise in genetic design and engineering.
Growing biotech investments indicate a robust market for Asimov's engineered cell lines.
Funding
Total raised$199.12 M
Latest valuation$875.00 M
StageSERIES_B
SERIES B
12/31/2022$175
$875.00 MSERIES A
11/30/2019$25
$125.00 MSEED
11/30/2017$5
$23.50 M